A possible 5'-NRIP1/UHRF1-3' fusion gene detected by array CGH analysis in a Ph+ ALL patient

Cancer Genetics

Volumn 204, Issue 12, 2011, Pages 687-691

  Zhang, Rui ^a,b   Kim, Young Mi ^a   Yang, Xiaohe ^c   Li, Yan ^b   Li, Shibo ^a   Lee, Ji Yun ^a,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^d Korea University College of Medicine   (South Korea)

Author keywords

ALL; Array CGH; Fusion gene; NRIP1; UHRF1

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 19P; CHROMOSOME 21Q; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FUSION GENE; HUMAN; HUMAN TISSUE; NRIP1 GENE; PRIORITY JOURNAL; UHRF1 GENE; CHROMOSOME 19; CHROMOSOME 21; GENE FUSION; GENE TRANSLOCATION; GENETICS; KARYOTYPE; KARYOTYPING; PHILADELPHIA 1 CHROMOSOME;

CCAAT ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; RECEPTOR INTERACTING PROTEIN 140; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UHRF1 PROTEIN, HUMAN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 21; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; KARYOTYPE; KARYOTYPING; NUCLEAR PROTEINS; ONCOGENE FUSION; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSLOCATION, GENETIC;

EID: 84858784176     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.11.006     Document Type: Article

References (26)

1. Huret JL. t(9;22)(q34;q11) in ALL. Atlas Genet Cytogenet Oncol Haematol. September 1997. http://AtlasGeneticsOncology.org/Anomalies/t0922ALL.html.
2. Li Y., Qiu L., Zou D., et al. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Ann Hematol 2009, 88:1069-1077.
3. Schilling G., Dierlamm J., Murga Penas E.M., et al. Dicentric (19;21)(p13;p13), a novel chromosomal abnormality occurring in a case of Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet 2004, 152:129-131.
4. Panani A.D., Dervenoulas J., Ferti A., et al. Acute lymphoblastic leukemia with a variant Philadelphia translocation, der(9), and der(19) chromosomes. Cancer Genet Cytogenet 1995, 80:162-164.
5. Struski S., Hélias C., Gervais C., et al. Confirmation of a novel recurrent association: BCR-ABL t(9;22) and t(19;21). Cancer Genet Cytogenet 2007, 179:127-131.
6. Baldwin E.L., Lee J.Y., Blake D.M., et al. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. Genet Med 2008, 10:415-429.
7. Wetzler M., Dodge R.K., Mrózek K., et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999, 93:3983-3993.
8. Greaves M.F., Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003, 3:639-649.
9. Pais A.P., Amare Kadam P.S., Raje G.C., et al. RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL. Pediatr Hematol Oncol 2008, 25:582-597.
10. Wiemels J.L., Hofmann J., Kang M., et al. Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally. Cancer Res 2008, 68:9935-9944.
11. Unoki M., Brunet J., Mousli M. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 2009, 78:1279-1288.
12. Bronner C., Achour M., Arima Y., et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future?. Pharmacol Ther 2007, 115:419-434.
13. Alhosin M., Abusnina A., Achour M., et al. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 2010, 79:1251-1260.
14. Pita J.M., Banito A., Cavaco B.M., et al. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 2009, 101:1782-1791.
15. Unoki M., Daigo Y., Koinuma J., et al. UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 2010, 103:217-222.
16. Heim K.C., White K.A., Deng D., et al. Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. Mol Cancer 2007, 6:57.
17. Fritah A., Christian M., Parker M.G. The metabolic coregulator RIP140: an update. Am J Physiol Endocrinol Metab 2010, 299(3):E335-E340.
18. Hopfner R., Mousli M., Jeltsch J.M., et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res 2000, 60:121-128.
19. Jenkins Y., Markovtsov V., Lang W., et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 2005, 16:5621-5629.
20. Jeanblanc M., Mousli M., Hopfner R., et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 2005, 24:7337-7345.
21. Cloos P.A., Christensen J., Agger K., et al. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008, 22:1115-1140.
22. Xiang Y., Zhu Z., Han G., et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007, 104:19226-19231.
23. Yang Z.Q., Imoto I., Fukuda Y., Pimkhaokham A., et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000, 60:4735-4739.
24. Yang J., Jubb A.M., Pike L., et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res 2010, 70:6456-6466.
25. Shi L., Sun L., Li Q., et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A 2011, 108:7541-7546.
26. Northcott P.A., Nakahara Y., Wu X., et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009, 41:465-472.